AI Article Synopsis
- Landiolol, a β1-selective beta-blocker, shows potential for rate control in critically ill patients with non-compensatory tachycardia, though its bolus formulation lacks extensive efficacy and safety data.
- A study on 30 patients revealed that 41% achieved successful heart rate control, with a significant reduction in average heart rate post-application, although blood pressure changes were clinically insignificant.
- Overall, the administration of push-dose Landiolol was found to be safe and effective, with no serious adverse events reported.
Article Abstract
Background: The highly β1-selective beta-blocker Landiolol is known to facilitate efficient and safe rate control in non-compensatory tachycardia or dysrhythmia when administered continuously. However, efficacy and safety data of the also-available bolus formulation in critically ill patients are scarce.
Methods: We conducted a retrospective cross-sectional study on a real-life cohort of critical care patients, who had been treated with push-dose Landiolol due to sudden-onset non-compensatory supraventricular tachycardia. Continuous hemodynamic data had been acquired via invasive blood pressure monitoring.
Results: Thirty patients and 49 bolus applications were analyzed. Successful heart rate control was accomplished in 20 (41%) cases, rhythm control was achieved in 13 (27%) episodes, and 16 (33%) applications showed no effect. Overall, the heart rate was significantly lower (145 (130-150) vs. 105 (100-125) bpm, < 0.001) in a 90 min post-application observational period in all subgroups. The median changes in blood pressure after the bolus application did not reach clinical significance. Compared with the ventilation settings before the bolus application, the respiratory settings including the required FiO after the bolus application did not differ significantly. No serious adverse events were seen.
Conclusions: Push-dose Landiolol was safe and effective in critically ill ICU patients. No clinically relevant impact on blood pressure was noted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967759 | PMC |
| http://dx.doi.org/10.3390/ph16020134 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Impact of Chronic Oral Beta-Blocker Intake on Intravenous Bolus Landiolol Response in Hospitalized Intensive Care Patients with Sudden-Onset Supraventricular Tachycardia-A Post Hoc Analysis of a Cross-Sectional Trial.
Pharmaceutics
June 2024
Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Landiolol, a highly cardioselective agent with a short half-life (2.4-4 min), is commonly used as a perfusor or bolus application to treat tachycardic arrhythmia. Some small studies suggest that prior oral β-blocker use results in a less effective response to intravenous β-blockers.
View Article and Find Full Text PDFHemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care-A Retrospective Cross-Sectional Study.
Pharmaceuticals (Basel)
January 2023
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.
Article Synopsis
- Landiolol, a β1-selective beta-blocker, shows potential for rate control in critically ill patients with non-compensatory tachycardia, though its bolus formulation lacks extensive efficacy and safety data.
- A study on 30 patients revealed that 41% achieved successful heart rate control, with a significant reduction in average heart rate post-application, although blood pressure changes were clinically insignificant.
- Overall, the administration of push-dose Landiolol was found to be safe and effective, with no serious adverse events reported.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!